Free Trial

Graybug Vision (GRAY) Competitors

Graybug Vision logo
$1.99 -0.08 (-3.86%)
As of 03/28/2025

GRAY vs. GOVX, APRE, CSCI, SNSE, MBRX, BLRX, TLPH, QNTM, TRAW, and APLM

Should you be buying Graybug Vision stock or one of its competitors? The main competitors of Graybug Vision include GeoVax Labs (GOVX), Aprea Therapeutics (APRE), COSCIENS Biopharma (CSCI), Sensei Biotherapeutics (SNSE), Moleculin Biotech (MBRX), BioLineRx (BLRX), Talphera (TLPH), Quantum Biopharma (QNTM), Traws Pharma (TRAW), and Apollomics (APLM). These companies are all part of the "pharmaceutical preparations" industry.

Graybug Vision vs.

GeoVax Labs (NASDAQ:GOVX) and Graybug Vision (NASDAQ:GRAY) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, community ranking, institutional ownership, media sentiment, dividends, valuation and profitability.

GeoVax Labs has a beta of 3.06, indicating that its share price is 206% more volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.

Graybug Vision's return on equity of -77.61% beat GeoVax Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
GeoVax LabsN/A -809.87% -349.34%
Graybug Vision N/A -77.61%-71.34%

GeoVax Labs has higher revenue and earnings than Graybug Vision. GeoVax Labs is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GeoVax Labs$3.09M3.27-$25.97M-$5.67-0.19
Graybug VisionN/AN/A-$35.60M-$24.23-0.08

GeoVax Labs received 10 more outperform votes than Graybug Vision when rated by MarketBeat users. Likewise, 96.30% of users gave GeoVax Labs an outperform vote while only 50.00% of users gave Graybug Vision an outperform vote.

CompanyUnderperformOutperform
GeoVax LabsOutperform Votes
26
96.30%
Underperform Votes
1
3.70%
Graybug VisionOutperform Votes
16
50.00%
Underperform Votes
16
50.00%

GeoVax Labs presently has a consensus target price of $14.20, suggesting a potential upside of 1,225.74%. Given GeoVax Labs' stronger consensus rating and higher probable upside, equities analysts plainly believe GeoVax Labs is more favorable than Graybug Vision.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GeoVax Labs
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.29
Graybug Vision
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 49.9% of Graybug Vision shares are owned by institutional investors. 5.7% of GeoVax Labs shares are owned by company insiders. Comparatively, 7.9% of Graybug Vision shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, GeoVax Labs had 13 more articles in the media than Graybug Vision. MarketBeat recorded 13 mentions for GeoVax Labs and 0 mentions for Graybug Vision. GeoVax Labs' average media sentiment score of 0.58 beat Graybug Vision's score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media.

Company Overall Sentiment
GeoVax Labs Positive
Graybug Vision Neutral

Summary

GeoVax Labs beats Graybug Vision on 13 of the 17 factors compared between the two stocks.

Remove Ads
Get Graybug Vision News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRAY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRAY vs. The Competition

MetricGraybug VisionPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3.13M$6.87B$5.61B$7.68B
Dividend YieldN/A2.79%5.33%4.02%
P/E Ratio-1.157.3523.5018.55
Price / SalesN/A208.36376.0088.66
Price / CashN/A65.6738.1734.64
Price / Book1.196.256.814.11
Net Income-$35.60M$142.34M$3.20B$247.18M
7 Day Performance-1.00%-8.43%-5.42%-4.05%
1 Month Performance-12.72%-9.99%-0.12%-6.41%
1 Year Performance-52.16%-12.60%7.61%-2.08%

Graybug Vision Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRAY
Graybug Vision
N/A$1.99
-3.9%
N/A-52.2%$3.13MN/A-1.1527High Trading Volume
GOVX
GeoVax Labs
3.0203 of 5 stars
$1.40
+6.9%
$14.20
+914.3%
-44.5%$12.36M$3.09M0.0010Earnings Report
Analyst Forecast
Short Interest ↓
Analyst Revision
APRE
Aprea Therapeutics
2.8654 of 5 stars
$2.26
-5.4%
$15.50
+585.8%
-68.8%$12.28M$580,000.00-0.807Earnings Report
Short Interest ↑
Analyst Revision
Gap Up
CSCI
COSCIENS Biopharma
N/A$3.22
+0.6%
N/AN/A$12.16M$7.60M-0.2720High Trading Volume
SNSE
Sensei Biotherapeutics
4.5411 of 5 stars
$0.46
-5.2%
$4.33
+832.7%
-51.6%$11.69MN/A-0.3940Earnings Report
Upcoming Earnings
Analyst Forecast
Short Interest ↓
Gap Down
MBRX
Moleculin Biotech
2.8814 of 5 stars
$1.06
-2.8%
$18.67
+1,661.0%
-82.4%$11.51MN/A0.0020Short Interest ↓
BLRX
BioLineRx
2.8056 of 5 stars
$3.42
-4.5%
$360.00
+10,426.3%
-93.2%$11.39M$21.99M-0.3940News Coverage
Gap Up
TLPH
Talphera
2.1041 of 5 stars
$0.64
+0.7%
$4.33
+578.0%
-43.1%$10.88M$281,000.00-0.9319Short Interest ↑
News Coverage
QNTM
Quantum Biopharma
N/A$5.55
-1.9%
N/AN/A$10.65MN/A-0.36N/AEarnings Report
News Coverage
Gap Up
TRAW
Traws Pharma
1.1708 of 5 stars
$2.84
flat
N/AN/A$10.37M$226,000.00-0.0217Upcoming Earnings
Gap Up
APLM
Apollomics
2.568 of 5 stars
$9.50
-4.0%
$200.00
+2,005.3%
-89.8%$10.33M$1.22M0.0045News Coverage
Gap Up
Remove Ads

Related Companies and Tools


This page (NASDAQ:GRAY) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners